Neurodiagnostics Market Size & Growth Forecast 2027–2036, By Segments (Technology, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to content
Market Size and Growth Outlook
Neurodiagnostics Market size was estimated at USD 20.6 billion in 2026 and is projected to grow at a 8.08% CAGR from 2027 to 2036, crossing USD 44.8 billion by 2036. The industry revenue for 2027 is assessed at USD 22 billion.
Get more details on this report
Request Free Sample ReportNeurodiagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 37.95% of the market in 2026, supported by advanced diagnostic infrastructure, high procedure volumes, and routine neurological testing across hospitals and specialty care settings.
- Asia Pacific is projected to expand at a 4.45% CAGR as healthcare systems improve neurological care, install more diagnostic equipment, and broaden patient access to specialized testing services.
Segment Momentum
- Neuroimaging Technologies accounted for 60.8% of the market in 2026 because they remain essential for visualizing neurological abnormalities, enabling faster interpretation and supporting routine diagnostic workflows across neurological conditions.
- Imaging Centers are growing fastest due to rising demand for specialized facilities that provide efficient imaging throughput and streamlined access to neurodiagnostic imaging services for patients and healthcare providers.
Market Expansion Drivers
- Rising neurological disorder prevalence increasing demand for advanced brain diagnostic technologies.
- AI-enabled neuroimaging improving diagnostic accuracy and early disease detection capabilities.
- Expanding geriatric population driving higher incidence of Alzheimer’s and Parkinson’s disease diagnostics.
Leading Market Participants
- Prominent players in the neurodiagnostics market include Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), GE HealthCare Technologies Inc. (United States), Canon Medical Systems Corporation (Japan), Nihon Kohden Corporation (Japan), Natus Medical Incorporated (United States), Compumedics Limited (Australia), Cadwell Industries, Inc. (United States), Advanced Brain Monitoring, Inc. (United States), FUJIFILM Holdings Corporation (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 20.6 billion
- 2027 Estimated Market Size: USD 22 billion.
- Projected Market Size: USD 44.8 billion by 2036
- Growth Forecast: 8.08% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Neuroimaging Technologies (Technology) | Hospitals & Clinics (End Use)
- Emerging Opportunity Segment: In Vitro Diagnostics (Technology) | Imaging Centers (End Use)
Market Growth Drivers and Industry Trends
Rising neurological disorder prevalence increasing demand for advanced brain diagnostic technologies
The increasing prevalence of neurological disorders is expanding the need for technologies that can identify and evaluate abnormalities affecting the brain and nervous system. Advanced diagnostic tools will drive the neurodiagnostics market growth by supporting clinicians in assessing neurological conditions more effectively, particularly as growing disease incidence increases the need for timely and detailed diagnostic evaluation.
AI-enabled neuroimaging improving diagnostic accuracy and early disease detection capabilities
Integration of artificial intelligence into neuroimaging is strengthening the ability to identify neurological abnormalities and interpret complex diagnostic information. AI-enabled tools will boost the neurodiagnostics market demand by supporting more accurate image analysis and earlier detection, helping healthcare providers identify potential disease-related changes while improving the efficiency of diagnostic workflows.
Expanding geriatric population driving higher incidence of Alzheimer’s and Parkinson’s disease diagnostics
The expanding elderly population is contributing to greater demand for diagnostic evaluation of age-associated neurological conditions, particularly alzheimer’s and parkinson’s disease. As these conditions require appropriate identification and assessment, the neurodiagnostics market is gaining from increased use of brain diagnostic technologies that help healthcare providers evaluate symptoms and support disease detection among older patients.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising neurological disorder prevalence increasing demand for advanced brain diagnostic technologies | 2.30% | High | North America, Europe, Asia Pacific | High | Near Term |
| AI-enabled neuroimaging improving diagnostic accuracy and early disease detection capabilities | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Expanding geriatric population driving higher incidence of Alzheimer’s and Parkinson’s disease diagnostics | 1.70% | High | Global | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the neurodiagnostics market, North America held the leading position with a 37.95% share in 2026, underpinned by advanced neurological care infrastructure, strong diagnostic capabilities, and extensive adoption of sophisticated technologies for evaluating disorders of the brain and nervous system. The region benefits from established clinical pathways for neurological assessment, widespread availability of specialized diagnostic facilities, and continued investment in technologies that support earlier and more accurate disease detection. Growing attention to neurological disorders, combined with increasing demand for non-invasive and technology-enabled diagnostic approaches, is strengthening the role of neurodiagnostics across hospitals, specialty centers, and research environments. Ongoing integration of advanced imaging, electrophysiological testing, and other diagnostic modalities further supports the region's market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, benefiting from expanding healthcare infrastructure, increasing neurological disease awareness, and improving access to specialized diagnostic services. Healthcare modernization across the region is enabling broader deployment of advanced diagnostic equipment, while rising demand for early detection and effective management of neurological conditions is encouraging greater investment in neurodiagnostic capabilities. The expansion of hospitals and specialty care facilities, together with greater availability of trained healthcare professionals and improved diagnostic awareness, is widening the addressable market. Increasing adoption of technologically advanced neurological assessment methods is also supporting the region's transition toward more sophisticated and accessible diagnostic care.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Precision Neurology FocusGermany is strengthening neurodiagnostic capabilities through advanced imaging and electrophysiological testing across specialized neurological centers. German healthcare institutions are prioritizing standardized diagnostic pathways that support accurate evaluation of complex neurological conditions.
France 🇫🇷
Integrated Neurology NetworksFrance is reinforcing coordinated neurodiagnostic services across hospitals and specialized neurological centers. French healthcare providers are focusing on efficient diagnostic pathways that support timely intervention for epilepsy, stroke, and neurodegenerative disorders.
Italy 🇮🇹
Hospital Diagnostic ModernizationItaly is modernizing neurodiagnostic infrastructure to improve access to advanced neurological assessments across regional healthcare systems. Italian hospitals are upgrading diagnostic equipment while expanding specialist capabilities for comprehensive neurological evaluation.
Japan 🇯🇵
Neuro Aging AssessmentJapan is expanding neurodiagnostic services to address growing demand associated with age-related neurological disorders. Healthcare providers in Japan are emphasizing early diagnosis and continuous monitoring supported by highly reliable diagnostic technologies.
South Korea 🇰🇷
AI-Enabled DiagnosticsSouth Korea is incorporating artificial intelligence into neurodiagnostic workflows to improve interpretation speed and diagnostic consistency. Hospitals across South Korea are investing in connected diagnostic platforms that strengthen neurological care delivery.
United States 🇺🇸
Advanced Diagnostic AdoptionThe U.S. continues investing in sophisticated neurodiagnostic technologies that support earlier detection of neurological disorders. Healthcare providers are integrating multimodal diagnostic platforms with digital workflows to improve clinical efficiency and patient management.
Neurodiagnostics Market Share (%), by Technology, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTechnology Segment Analysis: Neuroimaging Technologies (Largest Segment) vs In Vitro Diagnostics (Fastest-Growing Segment)
Neuroimaging technologies dominated the neurodiagnostics market in 2026, accounting for a 60.8% share, supported by their central role in identifying and evaluating neurological disorders through detailed visualization of brain and nervous system structures. Their broad clinical utility across diagnostic assessment, disease monitoring, and treatment planning strengthens adoption among healthcare providers. Continued demand for accurate and non-invasive neurological evaluation further reinforces the position of neuroimaging technologies, particularly where detailed anatomical and functional information is essential for clinical decision-making.
In vitro diagnostics are expected to register the fastest growth as neurodiagnostic practices increasingly incorporate laboratory-based approaches for identifying disease-related biomarkers and supporting more targeted clinical assessment. These methods can complement imaging by providing molecular and biochemical information that may aid earlier detection and more precise characterization of neurological conditions. Growing interest in personalized diagnosis and the expanding role of biomarker-based evaluation are supporting greater adoption of in vitro diagnostic approaches within neurological care.
End Use Segment Analysis: Hospitals & Clinics (Largest Segment) vs Imaging Centers (Fastest-Growing Segment)
The hospitals and clinics segment held the largest share of the neurodiagnostics market in 2026, representing 44.84% of the market, due to the concentration of neurological specialists, diagnostic infrastructure, and comprehensive patient-care capabilities within these settings. Hospitals and clinics can coordinate imaging, laboratory diagnostics, specialist consultations, and follow-up care, making them well suited to managing complex neurological conditions. Their ability to provide integrated diagnostic pathways continues to support strong utilization of neurodiagnostic technologies.
Imaging centers are poised for the fastest growth as diagnostic services increasingly shift toward specialized facilities designed to deliver efficient and focused imaging procedures. These centers provide dedicated diagnostic infrastructure and streamlined workflows, which can improve accessibility and convenience for patients requiring neurological imaging. Growing demand for specialized diagnostic services and the increasing emphasis on efficient outpatient evaluation are strengthening the role of imaging centers in neurodiagnostic care.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology | Neuroimaging Technologies, In Vitro Diagnostics, Neuroinformatics | Neuroimaging Technologies | In Vitro Diagnostics |
| End Use | Hospitals & Clinics, Diagnostic Laboratories, Imaging Centers, Others | Hospitals & Clinics | Imaging Centers |
Competitive Landscape and Market Positioning
Leading companies in the neurodiagnostics market:
1. Siemens Healthineers AG (Germany)
2. Koninklijke Philips N.V. (Netherlands)
3. GE HealthCare Technologies Inc. (United States)
4. Canon Medical Systems Corporation (Japan)
5. Nihon Kohden Corporation (Japan)
6. Natus Medical Incorporated (United States)
7. Compumedics Limited (Australia)
8. Cadwell Industries Inc. (United States)
9. Advanced Brain Monitoring Inc. (United States)
10. FUJIFILM Holdings Corporation (Japan)
Diagnostic intelligence systems are becoming more deeply embedded in neurological assessment workflows, enabling higher precision in detecting and analyzing brain-related disorders. Continuous advancements in analytical modeling and imaging integration are improving diagnostic speed and accuracy across clinical environments. The neurodiagnostics market is evolving through innovation in data-driven tools that enhance early detection capabilities and support more personalized neurological care pathways.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Siemens Healthineers AG (Germany) | |||||||
| Koninklijke Philips N.V. (Netherlands) | |||||||
| GE HealthCare Technologies Inc. (United States) | |||||||
| Canon Medical Systems Corporation (Japan) | |||||||
| Nihon Kohden Corporation (Japan) | |||||||
| Natus Medical Incorporated (United States) | |||||||
| Compumedics Limited (Australia) | |||||||
| Cadwell Industries Inc. (United States) | |||||||
| Advanced Brain Monitoring Inc. (United States) | |||||||
| FUJIFILM Holdings Corporation (Japan). |
Industry Development / News
| Company Name | Date | Key Development |
|---|---|---|
| EBRAINS | Jan-26 | EBRAINS became an associate partner in the European Partnership for Brain Health, a ten-year initiative valued at approximately USD 589.74 million involving over 55 institutions. The collaboration strengthens digital research infrastructure capabilities and supports coordinated advancement in neurological and mental health research across Europe. |
| Cadwell; Medical Informatics Corp | Dec-25 | Cadwell and Medical Informatics Corp formed a strategic partnership to integrate neurodiagnostic systems with the Sickbay Clinical Platform, enabling unified multimodal hospital data architecture. The collaboration establishes integrated clinical intelligence across neurodiagnostic devices, improving data interoperability and supporting advanced monitoring capabilities beyond traditional device-centric workflows. |
| Philips; SyntheticMR | Mar-24 | Philips partnered with SyntheticMR to introduce an AI-based quantitative brain imaging system aimed at improving detection and analysis of neurological conditions including multiple sclerosis, traumatic brain injury, and dementia. The solution enhances diagnostic precision through automated quantitative MRI processing. |
| Neurophet | Mar-24 | Neurophet launched AI-powered brain imaging analysis technology at AD/PD 2024, designed to assess brain atrophy and white matter hyperintensities in MRI scans. The solution supports improved diagnostic evaluation for Alzheimer’s disease and other neurodegenerative conditions through advanced image analytics. |
| Philips | Feb-24 | Philips launched the Azurion neuro biplane system at ECR 2024 to enhance minimally invasive neurovascular diagnosis and treatment. The system improves procedural speed and imaging precision, supporting expanded adoption of advanced interventional neurodiagnostic and treatment workflows in clinical settings. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Neurodiagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Indication | Epilepsy, Alzheimer’s Disease and Dementia, Parkinson’s Disease, Multiple Sclerosis, Stroke and Cerebrovascular Disorders, Other Neurological Disorders |
| Diagnostic Purpose | Disease Diagnosis, Disease Monitoring, Screening and Early Detection, Treatment Planning, Prognostic Assessment |
| Patient Demographics | Pediatric, Adult, Geriatric |
Neurodiagnostics Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Neurological Disease Screening Landscape |
|
| Artificial Intelligence Integration Opportunities |
|
| Diagnostic Workflow Transformation Analysis |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market valuation of neurodiagnostics?
How much is the neurodiagnostics industry expected to grow by 2036?
How is rising neurological disorder prevalence impacting demand in the neurodiagnostics market?
How is AI-enabled imaging and aging populations reshaping diagnostic approaches in the neurodiagnostics market?
Why do Neuroimaging Technologies lead the neurodiagnostics market?
Why are Imaging Centers the fastest-growing end-use segment in the neurodiagnostics market?
Why is North America the leading neurodiagnostics market?
What is accelerating neurodiagnostics market growth in Asia Pacific?
Which companies dominate the neurodiagnostics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook